Ignite Creation Date:
2025-12-25 @ 1:07 AM
Ignite Modification Date:
2026-01-01 @ 3:42 PM
Study NCT ID:
NCT00243893
Status:
COMPLETED
Last Update Posted:
2013-10-09
First Post:
2005-10-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000783', 'term': 'Aneurysm'}, {'id': 'D001165', 'term': 'Arteriovenous Malformations'}, {'id': 'C562573', 'term': 'cyclopia sequence'}], 'ancestors': [{'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D054079', 'term': 'Vascular Malformations'}, {'id': 'D018376', 'term': 'Cardiovascular Abnormalities'}, {'id': 'D000013', 'term': 'Congenital Abnormalities'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D008911', 'term': 'Minocycline'}, {'id': 'D004318', 'term': 'Doxycycline'}], 'ancestors': [{'id': 'D013754', 'term': 'Tetracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 26}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2004-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-10', 'completionDateStruct': {'date': '2008-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-10-08', 'studyFirstSubmitDate': '2005-10-24', 'studyFirstSubmitQcDate': '2005-10-24', 'lastUpdatePostDateStruct': {'date': '2013-10-09', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2005-10-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'MRI will be done baseline and post treatment.', 'timeFrame': '2 years'}, {'measure': 'MMP levels are being followed q 6-mos.', 'timeFrame': 'Patients called weekly for 1st-3 months, then every 6-months until completion of study'}, {'measure': 'Drug levels are being followed q 6-mos.', 'timeFrame': 'Patients called weekly for 1st-3 months, then every 6-months until completion of study'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['giant aneurysms', 'arteriovenous malformations', 'minocycline', 'doxycycline', 'BAVM'], 'conditions': ['Aneurysms', 'Arteriovenous Malformations']}, 'referencesModule': {'references': [{'pmid': '18212521', 'type': 'RESULT', 'citation': 'Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT, Guglielmo BJ, McCulloch CE, Young WL. Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis. 2008;25(1-2):157-63. doi: 10.1159/000113733. Epub 2008 Jan 23.'}], 'seeAlsoLinks': [{'url': 'http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605012/', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this pilot study is to investigate the use of minocycline and doxycycline as medical therapy for inoperable or partially treated arteriovenous malformations (AVMs) and giant aneurysms.', 'detailedDescription': 'Arteriovenous malformations (AVMs) are a treatable cause of stroke in young adults. The processes by which AVMs and giant aneurysms grow in size and spontaneously bleed are unknown. The primary reason to treat AVMs and aneurysms is to guard against intracranial bleeding.\n\nThis pilot study will examine the use of two common antibiotics-minocycline and doxycycline-as medical therapy for inoperable or partially treated AVMs and giant aneurysms. These drugs, which are tetracycline derivatives, can reduce the levels of a family of enzymes, called matrix metalloproteases, that degrade tissue and thereby cause a reduction in the risk of spontaneous bleeding from AVMs or aneurysm-which is the main cause of stroke associated with these disorders. The enzymes can contribute to weaknesses in the wall of blood vessels and may increase the risk of the vessel wall rupturing and causing spontaneous bleeding.\n\nThis trial also will show that taking minocycline and doxycycline over an extended period in this patient population is safe and well tolerated. Results from this study could help plan future studies to benefit patients with abnormal blood vessels prone to bleeding in their brains.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '13 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Giant aneurysms or brain arteriovenous malformations (BAVM)\n* Female patients of child bearing age using effective birth control, males\n* Creatinine no greater than 2.0 mg/dl\n* ALT no greater than 2 times upper limit of control\n\nExclusion Criteria:\n\n* Unstable medical illness\n* Contraindications to Tetracycline\n* History of vestibular disease, (except benign positional vertigo)\n* Prior tetracycline use within 2 mos of baseline visit.\n* History of noncompliance with treatment or other protocols\n* History of systemic lupus\n* Patients not eligible for MRI'}, 'identificationModule': {'nctId': 'NCT00243893', 'briefTitle': 'Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms', 'nctIdAliases': ['NCT00305994'], 'organization': {'class': 'OTHER', 'fullName': 'University of California, San Francisco'}, 'officialTitle': 'Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms', 'orgStudyIdInfo': {'id': 'R01NS027713', 'link': 'https://reporter.nih.gov/quickSearch/R01NS027713', 'type': 'NIH'}, 'secondaryIdInfos': [{'id': 'NS034949'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Brain AVMs', 'description': 'This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.', 'interventionNames': ['Drug: minocycline', 'Drug: doxycycline']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Aneurysms', 'interventionNames': ['Drug: minocycline', 'Drug: doxycycline']}], 'interventions': [{'name': 'minocycline', 'type': 'DRUG', 'description': 'Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.', 'armGroupLabels': ['Aneurysms', 'Brain AVMs']}, {'name': 'doxycycline', 'type': 'DRUG', 'description': 'Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.', 'armGroupLabels': ['Aneurysms', 'Brain AVMs']}]}, 'contactsLocationsModule': {'locations': [{'zip': '94143', 'city': 'San Francisco', 'state': 'California', 'country': 'United States', 'facility': 'University of California', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}], 'overallOfficials': [{'name': 'William L. Young, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of California, San Francisco'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of California, San Francisco', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Neurological Disorders and Stroke (NINDS)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}